Business Context and Reporting Period
This Form 8-K was filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on June 22, 2020, reporting a significant corporate event involving the sale of restricted common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a transaction involving equity ownership.
Material Changes
- Share Sale: Certain owners (Sellers) sold 1,512,465 shares of common stock to a healthcare-dedicated investment fund (the Fund).
- Lifting of Restrictions: The shares were previously subject to restrictions under a Leak-Out Agreement dated December 5, 2019. These restrictions were lifted via a Termination Agreement dated June 24, 2020, between the Company and the Fund.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed beyond the context of the share transfer and the termination of the prior leak-out agreement.
Investor Verification Checklist
- Verify the identity of the "Sellers" and the specific "healthcare-dedicated investment fund" involved in the transaction.
- Confirm the purchase price per share and total consideration paid, as these figures are not included in this summary text.
- Review the full Termination Agreement dated June 24, 2020, to understand any remaining obligations or conditions.
- Check subsequent filings for the impact of this transaction on the company's capital structure and insider ownership percentages.